{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VRC07-523LS+%28IV%29", "query": { "intervention": "VRC07-523LS (IV)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 15, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VRC07-523LS+%28IV%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T23:02:17.367Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03387150", "title": "Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "VRC07-523LS", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 124, "start_date": "2018-02-28", "completion_date": "2020-12-07", "has_results": true, "last_update_posted_date": "2023-04-05", "last_synced_at": "2026-09-25T23:02:17.367Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03387150" }, { "nct_id": "NCT03739996", "title": "Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Oral Cabotegravir (CAB)", "type": "DRUG" }, { "name": "Nucleoside Reverse Transcriptase Inhibitors (NRTIs)", "type": "DRUG" }, { "name": "Long-Acting Injectable Cabotegravir (CAB LA)", "type": "DRUG" }, { "name": "VRC07-523LS", "type": "BIOLOGICAL" }, { "name": "Standard of Care (SOC) ART", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2019-12-31", "completion_date": "2024-04-29", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-09-25T23:02:17.367Z", "location_count": 17, "location_summary": "Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03739996" }, { "nct_id": "NCT06987318", "title": "A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "VRC07-523LS", "type": "BIOLOGICAL" }, { "name": "PGT121.414.LS", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 40, "start_date": "2026-12-01", "completion_date": "2028-05-07", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-09-25T23:02:17.367Z", "location_count": 10, "location_summary": "Birmingham, Alabama • San Diego, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06987318" }, { "nct_id": "NCT05184452", "title": "A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "PGDM1400LS (5mg/kg, IV)", "type": "DRUG" }, { "name": "PGDM1400LS (20mg/kg, IV)", "type": "DRUG" }, { "name": "PGDM1400LS (20mg/kg, SC)", "type": "DRUG" }, { "name": "PGDM1400LS (40mg/kg, IV)", "type": "DRUG" }, { "name": "PGDM1400LS (40mg/kg, SC)", "type": "DRUG" }, { "name": "PGDM1400LS (1.4g, IV)", "type": "DRUG" }, { "name": "PGDM1400LS (1.4g, SC)", "type": "DRUG" }, { "name": "VRC07-523LS (20mg/kg, IV)", "type": "DRUG" }, { "name": "VRC07-523LS (20mg/kg, SC)", "type": "DRUG" }, { "name": "VRC07-523LS (1.4g, IV)", "type": "DRUG" }, { "name": "VRC07-523LS (1.4g, SC)", "type": "DRUG" }, { "name": "VRC07-523LS (40mg/kg, IV)", "type": "DRUG" }, { "name": "PGT121.414.LS (20mg/kg, IV)", "type": "DRUG" }, { "name": "PGT121.414.LS (20mg/kg, SC)", "type": "DRUG" }, { "name": "PGT121.414.LS (1.4g, IV)", "type": "DRUG" }, { "name": "PGT121.414.LS (1.4g, SC)", "type": "DRUG" }, { "name": "PGT121.414.LS (40mg/kg, IV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 95, "start_date": "2021-11-15", "completion_date": "2023-07-19", "has_results": true, "last_update_posted_date": "2025-02-10", "last_synced_at": "2026-09-25T23:02:17.367Z", "location_count": 5, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Newark", "state": "New Jersey" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05184452" }, { "nct_id": "NCT07390955", "title": "A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV" ], "interventions": [ { "name": "ePGT121v1-LS (IV)", "type": "BIOLOGICAL" }, { "name": "PGDM1400LS (IV)", "type": "BIOLOGICAL" }, { "name": "VRC07-523LS (IV)", "type": "BIOLOGICAL" }, { "name": "ePGT121v1-LS (SC)", "type": "BIOLOGICAL" }, { "name": "PGDM1400LS (SC)", "type": "BIOLOGICAL" }, { "name": "VRC07-523LS (SC)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 83, "start_date": "2026-03-19", "completion_date": "2027-08-30", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-25T23:02:17.367Z", "location_count": 7, "location_summary": "Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07390955" }, { "nct_id": "NCT07215468", "title": "HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV -1 Infection" ], "interventions": [ { "name": "TMB-365", "type": "DRUG" }, { "name": "TMB-380", "type": "DRUG" }, { "name": "Baseline ART", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TaiMed Biologics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2025-12-16", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-25T23:02:17.367Z", "location_count": 10, "location_summary": "San Francisco, California • Fort Lauderdale, Florida • Ft. Pierce, Florida + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Miami Gardens", "state": "Florida" }, { "city": "Oakland Park", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07215468" }, { "nct_id": "NCT02840474", "title": "Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1" ], "interventions": [ { "name": "VRC-HIVMAB080-00-AB", "type": "BIOLOGICAL" }, { "name": "VRC-HIVMAB075-00-AB", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 16, "start_date": "2017-04-24", "completion_date": "2020-01-15", "has_results": true, "last_update_posted_date": "2025-01-30", "last_synced_at": "2026-09-25T23:02:17.367Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Los Angeles, California • St Louis, Missouri + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02840474" }, { "nct_id": "NCT04340596", "title": "Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "N-803 (IL-15 Superagonist)", "type": "BIOLOGICAL" }, { "name": "VRC07-523LS", "type": "BIOLOGICAL" }, { "name": "10-1074", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 118, "start_date": "2021-05-21", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-25T23:02:17.367Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04340596" }, { "nct_id": "NCT06812494", "title": "A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV" ], "interventions": [ { "name": "VRC07-523LS 400mg", "type": "BIOLOGICAL" }, { "name": "PGT121.414.LS 400mg", "type": "BIOLOGICAL" }, { "name": "PGDM1400LS 400mg", "type": "BIOLOGICAL" }, { "name": "VRC07-523LS 3200mg", "type": "BIOLOGICAL" }, { "name": "PGT121.414.LS 1600mg", "type": "BIOLOGICAL" }, { "name": "PGDM1400LS 1600mg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 200, "start_date": "2025-03-07", "completion_date": "2027-09-15", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-25T23:02:17.367Z", "location_count": 13, "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06812494" }, { "nct_id": "NCT04212091", "title": "Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "PGT121.414.LS", "type": "BIOLOGICAL" }, { "name": "VRC07-523LS", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 33, "start_date": "2020-11-10", "completion_date": "2023-01-18", "has_results": true, "last_update_posted_date": "2024-12-13", "last_synced_at": "2026-09-25T23:02:17.367Z", "location_count": 5, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Decatur, Georgia + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04212091" } ] }